SYRS

AcronymDefinition
SYRSSystem Requirements Specification
SYRSSouth Yorkshire Rural Skills (UK)
SYRSSee You Real Soon
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
When Slawpase asks where Gyb's sheep are, John Horne replies, 'Now, syr, by my hode, / Yit se I no mo, / Not syn I here stode' (196-8).
B's plea to the audience to "fall to prayer, syrs, it is nede" (1.1221) has been for naught.
The 38 companies involved, employing some 20,000 people in Norway, are represented by the Federation of Norwegian Metallurgical Industries, Sigurd Syrs gate 4, N-0273 Oslo, Tel (+47 2) 44 84 80, fax 44 62 63 - the central contact for industry information.
Release date- 25072019 - CAMBRIDGE - Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m.
- US-based gene control medicines developer Syros Pharmaceuticals (NASDAQ: SYRS) presented new preclinical data across its franchise of selective cyclin-dependent kinase 7 inhibitors at the American Association for Cancer Research annual meeting in Atlanta, the company said.
Biotechnology company Syros Pharmaceuticals (NASDAQ: SYRS) stated on Thursday that it plans to offer shares of its common stock and Class A warrants to purchase common stock in an underwritten public offering.
Syros Pharmaceuticals (SYRS), down 4.8% after it filed to sell $40M in common stock.
As he sends his soldiers off on their mission, he warns: "If women wax woode; / I warn you, syrs, to spede you" (314-15).
- US-based gene control medicines developer Syros Pharmaceuticals (NASDAQ: SYRS) has released new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor, showing that it inhibits tumor cell growth in hormone receptor-positive (HR-positive) breast cancer cell lines that are resistant to treatment with CDK4/6 inhibitors and that it has synergistic activity in combination with fulvestrant in these treatment-resistant cells, the company said.
(NASDAQ: SYRS) shares rose 13.4% to close at $8.48 following strong quarterly sales.
- Data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor, demonstrated proof-of-mechanism at tolerable doses in patients with advanced solid tumors, US-based Syros Pharmaceuticals (NASDAQ: SYRS) said.